

Appendix 1. The frequency of drugs under investigation across different trials in COVID-19 therapeutics.

Drug candidate	Frequency	Percent of responses	Percent of cases
Chloroquine/hydroxychloroquine	31	13.6	25
Lopinavir	34	14.91	27.42
Ritonavir	38	16.67	30.65
Interferon alpha	22	9.65	17.74
Favipravir	9	3.95	7.26
ASCO9	1	0.44	0.81
Oseltamivir	2	0.88	1.61
Remdesvir	10	4.39	8.06
Umifenovir	9	3.95	7.26
Triazavirin	1	0.44	0.81
Baloxavir marboxil	2	0.88	1.61
Danoprevir	3	1.32	2.42
Azvudine	4	1.75	3.23
Sofosbuvir	2	0.88	1.61
Ledispasvir	1	0.44	0.81
Daclatasvir	1	0.44	0.81
Darunavir	6	2.63	4.84
Cobicistat	3	1.32	2.42
Emtricitabine	1	0.44	0.81
Tenofovir	1	0.44	0.81
Pirfenidone	3	1.32	2.42
Carimycin	2	0.88	1.61
Methylprednisolone	5	2.19	4.03
Tocilizumab	6	2.63	4.84
Adalimumab	2	0.88	1.61
Eculizumab	1	0.44	0.81
Sarilumab	1	0.44	0.81
Ixekizumab	1	0.44	0.81
Ribavirin	3	1.32	2.42
Bromhexine	1	0.44	0.81
Tranilast	1	0.44	0.81
Thymosin	3	1.32	2.42
Ebastine	1	0.44	0.81
Dexamethasone	1	0.44	0.81
Fingolimod	1	0.44	0.81

Drug candidate	Frequency	Percent of responses	Percent of cases
Meplazumab	1	0.44	0.81
Leflumide	1	0.44	0.81
Camrelizumab	1	0.44	0.81
Ulinastatin	1	0.44	0.81
Bevacizumab	2	0.88	1.61
Thalidomide	2	0.88	1.61
Suramin	1	0.44	0.81
Enoxaparin	1	0.44	0.81
Vitamin C	1	0.44	0.81
Tetrandine	1	0.44	0.81
Sildenafil	1	0.44	0.81
Heparin	1	0.44	0.81
Losartan	1	0.44	0.81